Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin’s lymphoma: phase I safety and efficacy

OBJECTIVE: HBI-8000 (tucidinostat) is a novel, oral histone deacetylase inhibitor that selectivity inhibits Class I (histone deacetylase 1, 2, 3) and Class II (histone deacetylase 10) with direct anti-tumor activity through various mechanisms of action, including epigenetic reprogramming and immunom...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimitsu, Makoto, Ando, Kiyoshi, Ishida, Takashi, Yoshida, Shinichiro, Choi, Ilseung, Hidaka, Michihiro, Takamatsu, Yasushi, Gillings, Mireille, Lee, Gloria T, Onogi, Hiroshi, Tobinai, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486889/
https://www.ncbi.nlm.nih.gov/pubmed/35649345
http://dx.doi.org/10.1093/jjco/hyac086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486889/
https://www.ncbi.nlm.nih.gov/pubmed/35649345
http://dx.doi.org/10.1093/jjco/hyac086

Ejemplares similares